Abstract:Background: Cancer cachexia is a debilitating syndrome associated with marked body loss because of muscular atrophy and fat loss. There are several mechanisms contributing to the pathogenesis of cachexia. The presence of the tumor releases cytokines from inflammatory and immune cells, which play a significant role in activating and deactivating certain pathways associated with protein, carbohydrate, and lipid metabolism. This review focuses on various cascades involving an imbalance between protein synthesis and degradation in the skeletal muscles. Objectives: This study aimed to elucidate the mechanisms involved in skeletal muscle wasting phenomenon over the last few years. Methods: This article briefly overviews different pathways responsible for muscle atrophy in cancer cachexia. Studies published up to April 2023 were included. Important findings and study contributions were chosen and compiled using several databases including PubMed, Google Scholar, Science Direct, and ClinicalTrials.gov using relevant keywords. Results: Cancer cachexia is a complex disease involving multiple factors resulting in atrophy of skeletal muscles. Systemic inflammation, altered energy balance and carbohydrate metabolism, altered lipid and protein metabolism, and adipose tissue browning are some of the major culprits in cancer cachexia. Increased protein degradation and decreased protein synthesis lead to muscle atrophy. Changes in signaling pathway like ubiquitin-proteasome, autophagy, mTOR, AMPK, and IGF-1 also lead to muscle wasting. Physical exercise, nutritional supplementation, steroids, myostatin inhibitors, and interventions targeting on inflammation have been investigated to treat cancer cachexia. Some therapy showed positive results in preclinical and clinical settings, although more research on the efficacy and safety of the treatment should be done. Conclusion: Muscle atrophy in cancer cachexia is the result of multiple complex mechanisms; as a result, a lot more research has been done to describe the pathophysiology of the disease. Targeted therapy and multimodal interventions can improve clinical outcomes for patients.

KLF10: a point of convergence in cancer cachexia

Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies

Cancer Cachexia: Signaling and Transcriptional Regulation of Muscle Catabolic Genes

Novel molecular targets of muscle wasting in cancer patients

Exploiting the therapeutic potential of leptin signaling in cachexia

Molecular Mechanisms of Cachexia: A Review

Cancer Cachexia in STK11/LKB1-mutated NSCLC is Dependent on Tumor-secreted GDF15

The TWEAK/Fn14 signaling promotes skeletal muscle wasting during cancer cachexia

Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting

Molecular mechanisms of cancer cachexia‐induced muscle atrophy (Review)

Understanding cachexia as a cancer metabolism syndrome

The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia

Circulating factors in cancer cachexia: recent opportunities for translational research

Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy

Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management

A TGF-β pathway associated with cancer cachexia

MC4 receptor antagonists: a potential treatment for cachexia

New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss

Targeting cancer cachexia: Molecular mechanisms and clinical study

Immune System Disorder and Cancer-Associated Cachexia

Inter-tissue communication in cancer cachexia